{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:04:41Z","timestamp":1781327081108,"version":"3.54.1"},"publisher-location":"Berlin, Heidelberg","reference-count":70,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642257605","type":"print"},{"value":"9783642257612","type":"electronic"}],"license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1007\/978-3-642-25761-2_10","type":"book-chapter","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T12:42:29Z","timestamp":1352119349000},"page":"241-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Interactions and Monitoring of Antipsychotic Drugs"],"prefix":"10.1007","author":[{"given":"Christoph","family":"Hiemke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pfuhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,28]]},"reference":[{"key":"10_CR0101","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2174\/1389450043490514","volume":"5","author":"T Baptista","year":"2004","unstructured":"Baptista T, Z\u00e1rate J, Joober R, Colasante C, Beaulieu S, P\u00e1ez X, Hern\u00e1ndez L (2004) Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 5:279\u2013299","journal-title":"Curr Drug Targets"},{"key":"10_CR0102","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","volume":"25","author":"TR Barnes","year":"2011","unstructured":"Barnes TR, Paton C (2011) Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 25:383\u2013399","journal-title":"CNS Drugs"},{"issue":"1","key":"10_CR0103","first-page":"S46","volume":"37","author":"S Bender","year":"2004","unstructured":"Bender S, Grohmann R, Engel RR, Degner D, Dittmann Balcar A, R\u00fcther E (2004) Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. Pharmacopsychiatry 37(1):S46\u2013S53","journal-title":"Pharmacopsychiatry"},{"key":"10_CR0104","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1067\/mcp.2002.121829","volume":"71","author":"LZ Benet","year":"2002","unstructured":"Benet LZ, Hoener B-A (2002) Changes in plasma binding have little clinical relevance. Clin Pharmacol Ther 71:115\u2013121","journal-title":"Clin Pharmacol Ther"},{"key":"10_CR0105","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.ftd.0000164609.14808.93","volume":"27","author":"G Bondolfi","year":"2005","unstructured":"Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB (2005) Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 27:539\u2013543","journal-title":"Ther Drug Monit"},{"key":"10_CR0106","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-3-642-14541-4_6","volume":"201","author":"I Cascorbi","year":"2011","unstructured":"Cascorbi I (2011) P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 201:261\u2013283","journal-title":"Handb Exp Pharmacol"},{"key":"10_CR0107","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.4088\/JCP.v68n1011","volume":"68","author":"I Castberg","year":"2007","unstructured":"Castberg I, Skogvoll E, Spigset O (2007) Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 68:1540\u20131545","journal-title":"J Clin Psychiatry"},{"key":"10_CR0109","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","volume":"56","author":"ML Chew","year":"2008","unstructured":"Chew ML, Mulsant BH, Poloock BG, Lehman ME, Greenspan A, Mahmoud RA, Kirshner MA, Sorisio DA, Bies RR, Gharabawi G (2008) Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 56:1333\u20131341","journal-title":"J Am Geriatr Soc"},{"key":"10_CR01010","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/01.pra.0000369968.80155.3f","volume":"16","author":"ML Cole","year":"2010","unstructured":"Cole ML, Trigoboff E, Demler TL, Opler LA (2010) Impact of smoking cessation on psychiatric inpatients treated with clozapine or olanzapine. J Psychiatr Pract 16:75\u201381","journal-title":"J Psychiatr Pract"},{"key":"10_CR01011","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s11095-006-0070-7","volume":"23","author":"WJ Crumb Jr","year":"2006","unstructured":"Crumb WJ Jr, Ekins S, Sarazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM Jr (2006) Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res 23:1133\u20131143","journal-title":"Pharm Res"},{"key":"10_CR01012","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/clpt.2011.70","volume":"90","author":"M Dobrinas","year":"2011","unstructured":"Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB (2011) Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 90:117\u2013125","journal-title":"Clin Pharmacol Ther"},{"key":"10_CR01013","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-pharmtox-010611-134529","volume":"52","author":"MK DeGorter","year":"2012","unstructured":"DeGorter MK, Xia CQ, Yang JJ, Kim RB (2012) Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 52:249\u2013273","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10_CR01014","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1067\/mcp.2000.112240","volume":"68","author":"D D\u00fcrr","year":"2000","unstructured":"D\u00fcrr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) St John\u2019s Wort induces intestinal P-glycoprotein\/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598\u2013604","journal-title":"Clin Pharmacol Ther"},{"key":"10_CR01015","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1742-7843.2005.pto_973160.x","volume":"97","author":"MS Faber","year":"2005","unstructured":"Faber MS, Jetter A, Fuhr U (2005) Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97:125\u2013134","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10_CR01016","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","volume":"49","author":"L Farde","year":"1992","unstructured":"Farde L, Nordstr\u00f6m AL, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538\u2013544","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR01017","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archpsyc.1988.01800250087012","volume":"45","author":"L Farde","year":"1988","unstructured":"Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71\u201376","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR01018","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-244X-5-26","volume":"5","author":"D Faries","year":"2005","unstructured":"Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J (2005) Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5:26","journal-title":"BMC Psychiatry"},{"key":"10_CR01019","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1034\/j.1600-0447.2002.01331.x","volume":"106","author":"O Freudenreich","year":"2002","unstructured":"Freudenreich O, Goff DC (2002) Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106:323\u2013330","journal-title":"Acta Psychiatr Scand"},{"key":"10_CR01020","first-page":"22","volume":"57","author":"AM Ghadirian","year":"1996","unstructured":"Ghadirian AM, Annable L, B\u00e9langer MC, Chouinard G (1996) A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 57:22\u201328","journal-title":"J Clin Psychiatry"},{"key":"10_CR01021","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.euroneuro.2009.04.003","volume":"19","author":"G Goodwin","year":"2009","unstructured":"Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O\u2019Keane V, Papakostas G, Vieta E, Zohar J (2009) Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 19:520\u2013532","journal-title":"Eur Neuropsychopharmacol"},{"key":"10_CR01022","series-title":"Handbook of experimental pharmacology","doi-asserted-by":"crossref","first-page":"XXx","DOI":"10.1007\/978-3-642-25761-2","volume-title":"Novel antischizophrenia treatments","author":"G Gross","year":"2012","unstructured":"Gross G, Drescher K (2012) The role of dopamine D3 receptors for antipsychotic activity and cognitive functions. In: Geyer M, Gross G (eds) Novel antischizophrenia treatments, vol 213, Handbook of Experimental Pharmacology. Springer, Berlin"},{"key":"10_CR01023","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","volume":"60","author":"G Gr\u00fcnder","year":"2003","unstructured":"Gr\u00fcnder G, Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60:974\u2013977","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR01024","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0031-1286282","volume":"44","author":"G Gr\u00fcnder","year":"2011","unstructured":"Gr\u00fcnder G, Hiemke C, Paulzen M, Veselinovic T, Vernaleken I (2011) Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry 44:236\u2013248","journal-title":"Pharmacopsychiatry"},{"key":"10_CR01025","unstructured":"Heal DJ, Gosden J, Jackson HC, Cheetham SC, Smith SL (2012) In: Gross G, Geyer M (ed) Current antipsychotics. Handbook of Experimental Pharmacology, vol 212. Springer, Berlin, pp xxx\u2013xxx"},{"key":"10_CR01026","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"C Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gr\u00fcnder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, M\u00fcller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry\u2014update 2011. Pharmacopsychiatry 44:195\u2013235","journal-title":"Pharmacopsychiatry"},{"key":"10_CR01027","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00228-004-0867-4","volume":"60","author":"J Jecel","year":"2005","unstructured":"Jecel J, Michel TM, Gutknecht L, Schmidt D, Pfuhlmann B, Jabs BE (2005) Toxic clozapine serum levels during acute urinary tract infection: a case report. Eur J Clin Pharmacol 60:909\u2013910","journal-title":"Eur J Clin Pharmacol"},{"key":"10_CR01028","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","volume":"33","author":"NH Jensen","year":"2008","unstructured":"Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine\u2019s antidepressant activity. Neuropsychopharmacology 33:2303\u20132312","journal-title":"Neuropsychopharmacology"},{"key":"10_CR01029","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","volume":"16","author":"M Jerling","year":"1994","unstructured":"Jerling M, Lindstr\u00f6m L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368\u2013374","journal-title":"Ther Drug Monit"},{"key":"10_CR01030","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1001\/jama.289.13.1652","volume":"289","author":"DN Juurlink","year":"2003","unstructured":"Juurlink DN, Mamdani MM, Kopp A, Laupacis A, Redelmeier DA (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. J Am Med Assoc 289:1652\u20131658","journal-title":"J Am Med Assoc"},{"key":"10_CR01031","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/HCO.0b013e32801129eb","volume":"22","author":"PC Kannakeril","year":"2007","unstructured":"Kannakeril PC, Roden DM (2007) Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 22:39\u201343","journal-title":"Curr Opin Cardiol"},{"key":"10_CR01032","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/archpsyc.57.6.553","volume":"57","author":"S Kapur","year":"2000","unstructured":"Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553\u2013559","journal-title":"Arch Gen Psychiatry"},{"key":"10_CR01033","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.155.7.921","volume":"155","author":"S Kapur","year":"1998","unstructured":"Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921\u2013928","journal-title":"Am J Psychiatry"},{"issue":"59","key":"10_CR01034","first-page":"474","volume":"2010","author":"KM Kirschbaum","year":"2011","unstructured":"Kirschbaum KM, Uhr M, Holthoewer D, Namendorf C, Pierzik C, Hiemke C, Schmitt U (2011) Pharmacokinetics of acute and subchronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 2010(59):474\u2013479","journal-title":"Neuropharmacology"},{"key":"10_CR01035","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5414\/CPP38504","volume":"38","author":"GI K\u00f6hler","year":"2000","unstructured":"K\u00f6hler GI, Bode-B\u00f6ger SM, Busse R, Hoopmann M, Welte T, B\u00f6ger RH (2000) Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 38:504\u2013513","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10_CR01036","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/sj.bjp.0706744","volume":"148","author":"S-O Lee","year":"2006","unstructured":"Lee S-O, Kim Y-J, Kim K-T, Choe H, Jo S-H (2006) Blockade of HERG human K+ channels on I\n                Kr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br J Pharmacol 148:499\u2013509","journal-title":"Br J Pharmacol"},{"key":"10_CR01037","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ijcard.2005.04.031","volume":"109","author":"KP Letsas","year":"2006","unstructured":"Letsas KP, Sideris A, Kounas SP, Efremidis M, Korantzopoulos P, Kardaras F (2006) Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol 109:273\u2013274","journal-title":"Int J Cardiol"},{"key":"10_CR01038","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1345\/aph.1M398","volume":"44","author":"EJ Lowe","year":"2000","unstructured":"Lowe EJ, Ackman ML (2010) Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother 44:727\u2013732","journal-title":"Ann Pharmacother"},{"key":"10_CR01039","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4088\/JCP.v61n0809","volume":"61","author":"ML Lu","year":"2000","unstructured":"Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH (2000) Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 61:594\u2013599","journal-title":"J Clin Psychiatry"},{"key":"10_CR01040","first-page":"391","volume":"76","author":"T Lynch","year":"2007","unstructured":"Lynch T, Price A (2007) The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76:391\u2013396","journal-title":"Am Fam Physician"},{"key":"10_CR01041","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1517\/17425255.4.7.895","volume":"4","author":"X Ma","year":"2008","unstructured":"Ma X, Idie J, Gonzalez FJ (2008) The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol 4:895\u2013908","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10_CR01042","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.euroneuro.2005.10.006","volume":"16","author":"R Medori","year":"2006","unstructured":"Medori R, Mannaert E, Gr\u00fcnder G (2006) Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol 16:233\u2013240","journal-title":"Eur Neuropsychopharmacol"},{"key":"10_CR01043","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1471-244X-11-118","volume":"11","author":"F Misawa","year":"2011","unstructured":"Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, Shida H, Oguchi Y, Okumura Y, Ito O, Kayama H (2011) Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross sectional study. BMC Psychiatry 11:118","journal-title":"BMC Psychiatry"},{"key":"10_CR01044","doi-asserted-by":"crossref","unstructured":"Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2011) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--A systematic review and meta-analysis. Schizophr Bull 2011 [Epub ahead of print]","DOI":"10.1093\/schbul\/sbr148"},{"key":"10_CR01045","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2217\/pgs.11.55","volume":"12","author":"T Moons","year":"2011","unstructured":"Moons T, de Roo M, Claes S, Dom G (2011) Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12:1193\u20131211","journal-title":"Pharmacogenomics"},{"key":"10_CR01046","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/FTD.0b013e3181b6326a","volume":"31","author":"A Nakamura","year":"2009","unstructured":"Nakamura A, Mihara K, Nagai G, Suzuki T, Kondo T (2009) Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit 31:575\u2013578","journal-title":"Ther Drug Monit"},{"issue":"suppl 1","key":"10_CR01047","first-page":"20","volume":"68","author":"JW Newcomer","year":"2007","unstructured":"Newcomer JW (2007) Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68(suppl 1):20\u201327","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10_CR01048","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/WNF.0b013e31816a1cc6","volume":"32","author":"T Nickl-Jockschat","year":"2009","unstructured":"Nickl-Jockschat T, Paulzen M, Schneider F, Gr\u00f6zinger M (2009) Drug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepine. Clin Neuropharmacol 32(1):55","journal-title":"Clin Neuropharmacol"},{"key":"10_CR01049","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3109\/00498254.2010.527021","volume":"41","author":"X Pang","year":"2011","unstructured":"Pang X, Cheng J, Krausz KW, Guo DA, Gonzalez FJ (2011) Pregnane X receptor-mediated induction of Cyp3a by black cohosh. Xenobiotica 41:112\u2013123","journal-title":"Xenobiotica"},{"key":"10_CR01050","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/JCP.0b013e3181acd20b","volume":"29","author":"B Pfuhlmann","year":"2009","unstructured":"Pfuhlmann B, Hiemke C, Unterecker S, Burger R, Schmidtke A, Riederer P, Deckert J, Jabs B (2009) Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol 29:392\u2013394","journal-title":"J Clin Psychopharmacol"},{"key":"10_CR01051","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","volume":"68","author":"E Richelsen","year":"2000","unstructured":"Richelsen E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 68:29\u201339","journal-title":"Life Sci"},{"issue":"10","key":"10_CR01052","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350(10):1013\u20131022","journal-title":"N Engl J Med"},{"key":"10_CR01053","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1172\/JCI25539","volume":"115","author":"DM Roden","year":"2005","unstructured":"Roden DM, Viswanthan PC (2005) Genetics of acquired long QT syndrome. J Clin Invest 115:2025\u20132032","journal-title":"J Clin Invest"},{"key":"10_CR01054","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hup.320","volume":"17","author":"P Rosenzweig","year":"2002","unstructured":"Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G (2002) A review of the pharmacokinetics tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol 17:1\u201313","journal-title":"Hum Psychopharmacol"},{"key":"10_CR01055","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1527-3458.2001.tb00200.x","volume":"7","author":"H Silver","year":"2001","unstructured":"Silver H (2001) Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7:283\u2013304","journal-title":"CNS Drug Rev"},{"key":"10_CR01056","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1358\/mf.2005.27.5.908643","volume":"27","author":"JS Silvestre","year":"2005","unstructured":"Silvestre JS, Prous J (2005) Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. J Methods Find Exp Clin Pharmacol 27:289\u2013304","journal-title":"J Methods Find Exp Clin Pharmacol"},{"key":"10_CR01057","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1208\/s12248-008-9037-4","volume":"10","author":"M Sinz","year":"2008","unstructured":"Sinz M, Wallace G, Sahi J (2008) Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 10:391\u2013400","journal-title":"AAPS J"},{"key":"10_CR01058","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","volume":"100","author":"E Spina","year":"2007","unstructured":"Spina E, de Leon J (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100:4\u201322","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10_CR01059","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","volume":"30","author":"E Spina","year":"2008","unstructured":"Spina E, Santoro V, D\u2019Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30:1206\u20131227","journal-title":"Clin Ther"},{"key":"10_CR01060","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1046\/j.1472-8206.2003.00193.x","volume":"17","author":"E Spina","year":"2003","unstructured":"Spina E, Scordo MG, D\u2019Arrigo C (2003) Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17:517\u2013538","journal-title":"Fundam Clin Pharmacol"},{"key":"10_CR01061","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1055\/s-2007-979221","volume":"32","author":"A Szegedi","year":"1999","unstructured":"Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, H\u00e4rtter S, Hiemke C, Wetzel H (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32:148\u2013153","journal-title":"Pharmacopsychiatry"},{"key":"10_CR01062","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0924-977X(02)00099-8","volume":"12","author":"PS Talbot","year":"2002","unstructured":"Talbot PS, Laruelle M (2002) The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12:503\u2013511","journal-title":"Eur Neuropsychopharmacol"},{"key":"10_CR01063","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00213-004-1802-1","volume":"175","author":"M Talvik","year":"2004","unstructured":"Talvik M, Nordstrom AL, Larsen NE, Jucaite A, Cervenka S, Halldin C, Farde L (2004) A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology 175:148\u2013153","journal-title":"Psychopharmacology"},{"key":"10_CR01064","first-page":"16","volume":"70","author":"JE Tisdale","year":"2011","unstructured":"Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM, Amankwa K, Borzak S, Kingery JR, Coram R, Zipes DP, Flockhart DA, Kovacs RJ (2011) Enhanced sensitivity to drug-induced QT interval lenthening in patients with heart failure due to left ventricular systolic dysfunction. J Clin Pharmacol 70:16\u201323","journal-title":"J Clin Pharmacol"},{"key":"10_CR01065","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2165\/00002018-200831010-00002","volume":"31","author":"C Tranulis","year":"2008","unstructured":"Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E (2008) Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 31:7\u201320","journal-title":"Drug Saf"},{"key":"10_CR01066","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1055\/s-0032-1326769","volume":"45","author":"S Unterecker","year":"2012","unstructured":"Unterecker S, Warrings B, Deckert J, Pfuhlmann B (2012) Correlation of QTc interval-prolongation and serum level of citalopram after intoxication \u2013 a case report. Pharmacopsychiatry 45:30\u201334","journal-title":"Pharmacopsychiatry"},{"key":"10_CR01067","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2125.2010.03660.x","volume":"70","author":"C van Noord","year":"2010","unstructured":"van Noord C, Eijgelsheim M, Stricker BH (2010) Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 70:16\u201323","journal-title":"Br J Clin Pharmacol"},{"key":"10_CR01068","first-page":"687","volume":"108","author":"K Wenzel-Seifert","year":"2011","unstructured":"Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsades de pointes. Dtsch \u00c4rztebl Int 108:687\u2013693","journal-title":"Dtsch Arztebl Int"},{"key":"10_CR01069","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/09540260701564849","volume":"19","author":"DF Wong","year":"2007","unstructured":"Wong DF, Gr\u00fcnder G, Brasic JR (2007) Brain imaging research: does the science serve clinical practice? Int Rev Psychiatry 19:541\u2013558","journal-title":"Int Rev Psychiatry"},{"key":"10_CR01070","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","volume":"48","author":"SF Zhou","year":"2009","unstructured":"Zhou SF (2009) Polymorphims of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 48:761\u2013804","journal-title":"Clin Pharmacokinet"},{"key":"10_CR01071","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1517\/17425250903578642","volume":"6","author":"BT Zhu","year":"2010","unstructured":"Zhu BT (2010) On the general mechanism of selective induction of cytochrome P450 enzymes by chemicals: some theoretical considerations. Expert Opin Drug Metab Toxicol 6:483\u2013494","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Handbook of Experimental Pharmacology","Current Antipsychotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-25761-2_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T19:12:57Z","timestamp":1674846777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-25761-2_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"ISBN":["9783642257605","9783642257612"],"references-count":70,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-25761-2_10","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]},"assertion":[{"value":"28 September 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}